Carlsmed Inc. (CARL)
NASDAQ: CARLHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CARL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $477.38M
- EPS (TTM)
- -$1.13
- Dividend yield
- None
- 52-week range
- 8.50 – 19.15
- Day range
- 16.91 – 18.25
- Volume / Avg
- 261.68K / 112.80K
- Beta
- —
- Shares outstanding
- 27.40M
52-week range
CARL stock today
On Nov 20, CARL ended the session at $17.42, adding $0.20 (1.16%), versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 261.68K shares, a sign of unusually heavy trading. At this level, CARL sits near the top of its 52-week range of $8.50 to $19.15: 9.0% below the high, set on Nov 11, 2026 and 104.9% above the low.
CARL is up 41.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 39.5%. Carlsmed has posted a net loss over the last twelve months (EPS of -$1.13), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Carlsmed
Company profileCarlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Michael John Cordonnier
- Headquarters
- Carlsbad, CA
- Employees
- 127
- IPO year
- 2025
- Website
- carlsmed.com
Financial highlights
Full financialsIn fiscal 2025, Carlsmed generated $50.5 million in revenue, up 85.9% from fiscal 2024. Carlsmed reported a net loss of $29.6 million, compared with a loss of $24.3 million a year earlier. Gross margin was 75.3% (up from 73.8%) and operating margin -60.5%.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | $50.51M | $27.16M |
| Growth | +85.94% | — |
| Net income | $-29.63M | $-24.26M |
| EPS (diluted) | $-2.12 | $-6.11 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$22.00+26.29%
- Strong buy 2
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.40 vs $-0.42
- Surprise
- +4.76%
CARL news
All CARL news- Carlsmed to Participate in Upcoming Investor ConferencesGlobeNewswire
- Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year GuidanceGlobeNewswire
- Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026GlobeNewswire
- Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior SystemGlobeNewswire
Carlsmed peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ANGOAngioDynamics Inc. | 10.81 | +0.46% | $454.61M | vs CARL |
| RCELAvita Medical Inc. | 15.62 | -2.31% | $494.96M | vs CARL |
| MDXGMiMedx Group Inc | 3.05 | -1.93% | $445.07M | vs CARL |
| SENSSenseonics Holdings Inc. | 8.02 | -9.94% | $439.34M | vs CARL |
| SIShoulder Innovations Inc. | 20.15 | -0.79% | $421.58M | vs CARL |
| MOBIMobia Medical Inc. | 11.85 | -0.08% | $394.50M | vs CARL |
| SGHTSight Sciences Inc. | 10.18 | -4.14% | $565.79M | vs CARL |
| CERSCerus Corporation | 1.85 | -2.63% | $373.62M | vs CARL |
Indexes, lists and sector
Carlsmed stock FAQ
What is Carlsmed's stock price today?
CARL last traded at $17.42 as of Nov 20, 4:00 PM EST, up 1.16% on the day. Prices are delayed at least 15 minutes.
Who is Carlsmed's CEO?
Mr. Michael John Cordonnier is the chief executive officer of Carlsmed Inc., which has about 127 employees.
What is the CARL 52-week high?
The 52-week high for CARL is $19.15 and the 52-week low is $8.50. The stock is currently 9.0% below its high.